out showing any correlation between pre-CRT s-CEA level and pathologic tumor response [5]. Presently, few biomarkers are considered promising as CRT-predictive markers. The s-CEA level of preor post-CRT appears to be closely associated with the prognosis in LARC patients, but its predictive value for pathologic response needs to be further verified. Additionally, efficient individualized regime...

The current study reports the results of an open label pilot study evaluating a novel treatment protocol for patients with locally advanced head and neck cancer. Patients received induction chemotherapy and those who had a clinical complete response to induction chemotherapy were offered trans-oral nidusectomy for the primary lesion and neck node dissection. If a pathologic complete response wa...

PURPOSE Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes. EXPERIMENTAL DESIGN We used immunohistochemical profiles [human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-negative for HER2+/estrogen receptor-negative (ER-), hormone receptor and...

PURPOSE Little information exists about the possible influence of serum HER2/neu on response to chemotherapy. We propose that the assessment of serum HER2/neu in a pretreatment serum sample may be useful in predicting response to neoadjuvant chemotherapy. METHODS All breast cancer patients were tested by immunohistochemical stain and fluorescent in situ hybridization for HER2/neu before treat...

BACKGROUND AND PURPOSE To correlate changes of various CT parameters after the neoadjuvant treatment in patients with lung adenocarcinoma with pathologic responses, focused on their relationship with different therapeutic options, particularly of EGFR-TKI and concurrent chemoradiation therapy (CCRT) settings. MATERIALS AND METHODS We reviewed pre-operative CT images of primary tumors and surg...